Simultaneous allowance for p53 and ER in survival analysis of patients with early breast cancer, where the presence of ER is a favorable prognostic factor [31-34], and predicts the efficacy of endocrine therapies [31], has yielded conflicting results. This evidence concerns the gene TP53 and breast cancer.